Martina M. McGrathRenal Division, Brigham and Women’s Hospital, Boston, Massachusetts Renal Division, Veterans Affairs Boston Healthcare System, Boston, Massachusetts
SeifterJL, ChangH-Y: Extracellular acid-base balance and ion transport between body fluid compartments. Physiology (Bethesda)32: 367–379, 2017PubMed
SeifterJL, ChangH-Y: Extracellular acid-base balance and ion transport between body fluid compartments. Physiology (Bethesda) 32: 367–379, 2017PubMed)| false
KrautJA, MadiasNE: Re-evaluation of the normal range of serum total CO2 concentration. Clin J Am Soc Nephrol 13: 343–347, 2018PubMed10.2215/CJN.11941017)| false
ErreaA, CayetD, MarchettiP, TangC, KluzaJ, OffermannsS, et al.: Lactate inhibits the pro-inflammatory response and metabolic reprogramming in murine macrophages in a GPR81-independent manner. PLoS One11: e0163694, 2016PubMed
ErreaA, CayetD, MarchettiP, TangC, KluzaJ, OffermannsS, : Lactate inhibits the pro-inflammatory response and metabolic reprogramming in murine macrophages in a GPR81-independent manner. PLoS One 11: e0163694, 2016PubMed10.1371/journal.pone.0163694)| false
RudkinSE, GroganTR, TregerRM: The Δ anion gap/Δ bicarbonate ratio in early lactic acidosis: Time for another delta?https://kidney360.asnjournals.org/content/2/1/20. Kidney360 2: 20–25, 202010.34067/KID.0000842019)| false
YunosNM, BellomoR, HegartyC, StoryD, HoL, BaileyM: Association between a chloride-liberal vs chloride-restrictive intravenous fluid administration strategy and kidney injury in critically ill adults. JAMA308: 1566–1572, 2012PubMed
YunosNM, BellomoR, HegartyC, StoryD, HoL, BaileyM: Association between a chloride-liberal vs chloride-restrictive intravenous fluid administration strategy and kidney injury in critically ill adults. JAMA 308: 1566–1572, 2012PubMed10.1001/jama.2012.13356)| false
RaghunathanK, BonaviaA, NathansonBH, BeadlesCA, ShawAD, BrookhartMA, et al.: Association between initial fluid choice and subsequent in-hospital mortality during the resuscitation of adults with septic shock. Anesthesiology123: 1385–1393, 2015PubMed
RaghunathanK, BonaviaA, NathansonBH, BeadlesCA, ShawAD, BrookhartMA, : Association between initial fluid choice and subsequent in-hospital mortality during the resuscitation of adults with septic shock. Anesthesiology 123: 1385–1393, 2015PubMed10.1097/ALN.0000000000000861)| false
SemlerMW, SelfWH, WandererJP, EhrenfeldJM, WangL, ByrneDW, et al.; SMART Investigators and the Pragmatic Critical Care Research Group: Balanced crystalloids versus saline in critically ill adults. N Engl J Med378: 829–839, 2018PubMed
SemlerMW, SelfWH, WandererJP, EhrenfeldJM, WangL, ByrneDW, ; SMART Investigators and the Pragmatic Critical Care Research Group: Balanced crystalloids versus saline in critically ill adults. N Engl J Med 378: 829–839, 2018PubMed10.1056/NEJMoa1711584)| false
SelfWH, EvansCS, JenkinsCA, BrownRM, CaseyJD, CollinsSP, et al.; Pragmatic Critical Care Research Group: Clinical effects of balanced crystalloids vs saline in adults with diabetic ketoacidosis: A subgroup analysis of cluster randomized clinical trials. JAMA Netw Open3: e2024596, 2020PubMed
SelfWH, EvansCS, JenkinsCA, BrownRM, CaseyJD, CollinsSP, ; Pragmatic Critical Care Research Group: Clinical effects of balanced crystalloids vs saline in adults with diabetic ketoacidosis: A subgroup analysis of cluster randomized clinical trials. JAMA Netw Open 3: e2024596, 2020PubMed10.1001/jamanetworkopen.2020.24596)| false
GroupKDIGO; Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group: KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int 98[4S]: S1–S115, 2020PubMed10.1016/j.kint.2020.06.019)| false
FerranniniE, BaldiS, FrascerraS, AstiarragaB, HeiseT, BizzottoR, et al.: Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes65: 1190–1195, 2016PubMed
FerranniniE, BaldiS, FrascerraS, AstiarragaB, HeiseT, BizzottoR, : Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes 65: 1190–1195, 2016PubMed10.2337/db15-1356)| false
PalmerBF, CleggDJ: Euglycemic ketoacidosis as a complication of SGLT2 inhibitor therapy. Clin J Am Soc Nephrol 16: 1284–1291, 2021PubMed10.2215/CJN.17621120)| false
EronduN, DesaiM, WaysK, MeiningerG: Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program. Diabetes Care38: 1680–1686, 2015PubMed
EronduN, DesaiM, WaysK, MeiningerG: Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program. Diabetes Care 38: 1680–1686, 2015PubMed10.2337/dc15-1251)| false
DonnanK, SegarL: SGLT2 inhibitors and metformin: Dual antihyperglycemic therapy and the risk of metabolic acidosis in type 2 diabetes. Eur J Pharmacol846: 23–29, 2019PubMed
DonnanK, SegarL: SGLT2 inhibitors and metformin: Dual antihyperglycemic therapy and the risk of metabolic acidosis in type 2 diabetes. Eur J Pharmacol 846: 23–29, 2019PubMed10.1016/j.ejphar.2019.01.002)| false
TingS, ChuaH-R, CoveME: Euglycemic ketosis during continuous kidney replacement therapy with glucose-free solution: A report of 8 cases. Am J Kidney Dis78: 305–308, 2021PubMed
JiangJ, ChanA, AliS, SahaA, HaushalterKJ, LamWL, et al.: Hydrogen sulfide--mechanisms of toxicity and development of an antidote. Sci Rep6: 20831, 2016PubMed
JiangJ, ChanA, AliS, SahaA, HaushalterKJ, LamWL, : Hydrogen sulfide--mechanisms of toxicity and development of an antidote. Sci Rep 6: 20831, 2016PubMed10.1038/srep20831)| false
HundemerGL, FenvesAZ, PhillipsKM, EmmettM: Sodium thiosulfate and the anion gap in patients treated by hemodialysis. Am J Kidney Dis68: 499–500, 2016PubMed
HundemerGL, FenvesAZ, PhillipsKM, EmmettM: Sodium thiosulfate and the anion gap in patients treated by hemodialysis. Am J Kidney Dis 68: 499–500, 2016PubMed10.1053/j.ajkd.2016.02.040)| false
ReinJL, MiyataKN, DadzieKA, GruberSJ, SulicaR, WinchesterJF: Successfully treated calcific uremic arteriolopathy: Two cases of a high anion gap metabolic acidosis with intravenous sodium thiosulfate. Case Rep Nephrol2014: 765134, 2014PubMed
ReinJL, MiyataKN, DadzieKA, GruberSJ, SulicaR, WinchesterJF: Successfully treated calcific uremic arteriolopathy: Two cases of a high anion gap metabolic acidosis with intravenous sodium thiosulfate. Case Rep Nephrol 2014: 765134, 2014PubMed)| false
MaoM, LeeS, KashaniK, AlbrightR, QianQ: Severe anion gap acidosis associated with intravenous sodium thiosulfate administration. J Med Toxicol9: 274–277, 2013PubMed
MarianoF, BianconeL: Metformin, chronic nephropathy and lactic acidosis: A multi-faceted issue for the nephrologist. J Nephrol34: 1127–1135, 2021PubMed
MarianoF, BianconeL: Metformin, chronic nephropathy and lactic acidosis: A multi-faceted issue for the nephrologist. J Nephrol 34: 1127–1135, 2021PubMed10.1007/s40620-020-00941-8)| false
HundalRS, KrssakM, DufourS, LaurentD, LebonV, ChandramouliV, et al.: Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes49: 2063–2069, 2000PubMed
HundalRS, KrssakM, DufourS, LaurentD, LebonV, ChandramouliV, : Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 49: 2063–2069, 2000PubMed10.2337/diabetes.49.12.2063)| false
AlvarezCA, HalmEA, PughMJV, McGuireDK, HennessyS, MillerRT, et al.: Lactic acidosis incidence with metformin in patients with type 2 diabetes and chronic kidney disease: A retrospective nested case-control study. Endocrinol Diabetes Metab4: e00170, 2020PubMed
AlvarezCA, HalmEA, PughMJV, McGuireDK, HennessyS, MillerRT, : Lactic acidosis incidence with metformin in patients with type 2 diabetes and chronic kidney disease: A retrospective nested case-control study. Endocrinol Diabetes Metab 4: e00170, 2020PubMed)| false
CalelloDP, LiuKD, WiegandTJ, RobertsDM, LavergneV, GosselinS, et al.; Extracorporeal Treatments in Poisoning Workgroup: Extracorporeal treatment for metformin poisoning: Systematic review and recommendations from the Extracorporeal Treatments in Poisoning Workgroup. Crit Care Med43: 1716–1730, 2015PubMed
CalelloDP, LiuKD, WiegandTJ, RobertsDM, LavergneV, GosselinS, ; Extracorporeal Treatments in Poisoning Workgroup: Extracorporeal treatment for metformin poisoning: Systematic review and recommendations from the Extracorporeal Treatments in Poisoning Workgroup. Crit Care Med 43: 1716–1730, 2015PubMed10.1097/CCM.0000000000001002)| false
Kidney Disease: Improving Global Outcomes. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Available at: https://kdigo.org/wp-content/uploads/2017/02/KDIGO_2012_CKD_GL.pdf. Accessed October 31, 2021)| false
GennariFJ, HoodVL, GreeneT, WangX, LeveyAS: Effect of dietary protein intake on serum total CO2 concentration in chronic kidney disease: Modification of Diet in Renal Disease study findings. Clin J Am Soc Nephrol1: 52–57, 2006PubMed
GennariFJ, HoodVL, GreeneT, WangX, LeveyAS: Effect of dietary protein intake on serum total CO2 concentration in chronic kidney disease: Modification of Diet in Renal Disease study findings. Clin J Am Soc Nephrol 1: 52–57, 2006PubMed10.2215/CJN.00060505)| false
PhisitkulS, KhannaA, SimoniJ, BroglioK, SheatherS, RajabMH, et al.: Amelioration of metabolic acidosis in patients with low GFR reduced kidney endothelin production and kidney injury, and better preserved GFR. Kidney Int77: 617–623, 2010PubMed
PhisitkulS, KhannaA, SimoniJ, BroglioK, SheatherS, RajabMH, : Amelioration of metabolic acidosis in patients with low GFR reduced kidney endothelin production and kidney injury, and better preserved GFR. Kidney Int 77: 617–623, 2010PubMed10.1038/ki.2009.519)| false
DriverTH, ShlipakMG, KatzR, GoldensteinL, SarnakMJ, HoofnagleAN, et al.: Low serum bicarbonate and kidney function decline: The Multi-Ethnic Study of Atherosclerosis (MESA). Am J Kidney Dis64: 534–541, 2014PubMed
DriverTH, ShlipakMG, KatzR, GoldensteinL, SarnakMJ, HoofnagleAN, : Low serum bicarbonate and kidney function decline: The Multi-Ethnic Study of Atherosclerosis (MESA). Am J Kidney Dis 64: 534–541, 2014PubMed10.1053/j.ajkd.2014.05.008)| false
MoranneO, FroissartM, RossertJ, GauciC, BoffaJJ, HaymannJP, et al.; NephroTest Study Group: Timing of onset of CKD-related metabolic complications. J Am Soc Nephrol20: 164–171, 2009PubMed
GorayaN, SimoniJ, SagerLN, MadiasNE, WessonDE: Urine citrate excretion as a marker of acid retention in patients with chronic kidney disease without overt metabolic acidosis. Kidney Int95: 1190–1196, 2019PubMed
GorayaN, SimoniJ, SagerLN, MadiasNE, WessonDE: Urine citrate excretion as a marker of acid retention in patients with chronic kidney disease without overt metabolic acidosis. Kidney Int 95: 1190–1196, 2019PubMed10.1016/j.kint.2018.11.033)| false
ShahSN, AbramowitzM, HostetterTH, MelamedML: Serum bicarbonate levels and the progression of kidney disease: A cohort study. Am J Kidney Dis54: 270–277, 2009PubMed
ShahSN, AbramowitzM, HostetterTH, MelamedML: Serum bicarbonate levels and the progression of kidney disease: A cohort study. Am J Kidney Dis 54: 270–277, 2009PubMed10.1053/j.ajkd.2009.02.014)| false
DobreM, YangW, PanQ, AppelL, BellovichK, ChenJ, et al.; CRIC Study Investigators: Persistent high serum bicarbonate and the risk of heart failure in patients with chronic kidney disease (CKD): A report from the Chronic Renal Insufficiency Cohort (CRIC) study. J Am Heart Assoc4: e001599, 2015PubMed
DobreM, YangW, PanQ, AppelL, BellovichK, ChenJ, ; CRIC Study Investigators: Persistent high serum bicarbonate and the risk of heart failure in patients with chronic kidney disease (CKD): A report from the Chronic Renal Insufficiency Cohort (CRIC) study. J Am Heart Assoc 4: e001599, 2015PubMed10.1161/JAHA.114.001599)| false
WessonDE, SimoniJ, BroglioK, SheatherS: Acid retention accompanies reduced GFR in humans and increases plasma levels of endothelin and aldosterone. Am J Physiol Renal Physiol300: F830–F837, 2011PubMed
WessonDE, SimoniJ, BroglioK, SheatherS: Acid retention accompanies reduced GFR in humans and increases plasma levels of endothelin and aldosterone. Am J Physiol Renal Physiol 300: F830–F837, 2011PubMed10.1152/ajprenal.00587.2010)| false
NathKA, HostetterMK, HostetterTH: Increased ammoniagenesis as a determinant of progressive renal injury. Am J Kidney Dis 17: 654–657, 1991PubMed10.1016/S0272-6386(12)80344-1)| false
Di IorioBR, BellasiA, RaphaelKL, SantoroD, AucellaF, GarofanoL, et al.; UBI Study Group: Treatment of metabolic acidosis with sodium bicarbonate delays progression of chronic kidney disease: The UBI Study. J Nephrol32: 989–1001, 2019PubMed
Di IorioBR, BellasiA, RaphaelKL, SantoroD, AucellaF, GarofanoL, ; UBI Study Group: Treatment of metabolic acidosis with sodium bicarbonate delays progression of chronic kidney disease: The UBI Study. J Nephrol 32: 989–1001, 2019PubMed10.1007/s40620-019-00656-5)| false
RaphaelKL, IsakovaT, IxJH, RajDS, WolfM, FriedLF, et al.: A randomized trial comparing the safety, adherence, and pharmacodynamics profiles of two doses of sodium bicarbonate in CKD: The BASE Pilot Trial. J Am Soc Nephrol31: 161–174, 2020PubMed
RaphaelKL, IsakovaT, IxJH, RajDS, WolfM, FriedLF, : A randomized trial comparing the safety, adherence, and pharmacodynamics profiles of two doses of sodium bicarbonate in CKD: The BASE Pilot Trial. J Am Soc Nephrol 31: 161–174, 2020PubMed10.1681/ASN.2019030287)| false
NavaneethanSD, ShaoJ, BuysseJ, BushinskyDA: Effects of treatment of metabolic acidosis in CKD: A systematic review and meta-analysis. Clin J Am Soc Nephrol14: 1011–1020, 2019
NavaneethanSD, ShaoJ, BuysseJ, BushinskyDA: Effects of treatment of metabolic acidosis in CKD: A systematic review and meta-analysis. Clin J Am Soc Nephrol 14: 1011–1020, 201910.2215/CJN.13091118)| false
WithamMD, et al.; BiCARB study group: Clinical and cost-effectiveness of oral sodium bicarbonate therapy for older patients with chronic kidney disease and low-grade acidosis (BiCARB): A pragmatic randomised, double-blind, placebo-controlled trial. BMC Med18: 91, 2020PubMed
WithamMD, ; BiCARB study group: Clinical and cost-effectiveness of oral sodium bicarbonate therapy for older patients with chronic kidney disease and low-grade acidosis (BiCARB): A pragmatic randomised, double-blind, placebo-controlled trial. BMC Med 18: 91, 2020PubMed10.1186/s12916-020-01542-9)| false
KendrickJ, ShahP, AndrewsE, YouZ, NowakK, PaschA, et al.: Effect of treatment of metabolic acidosis on vascular endothelial function in patients with CKD: A pilot randomized cross-over study. Clin J Am Soc Nephrol13: 1463–1470, 2018PubMed
KendrickJ, ShahP, AndrewsE, YouZ, NowakK, PaschA, : Effect of treatment of metabolic acidosis on vascular endothelial function in patients with CKD: A pilot randomized cross-over study. Clin J Am Soc Nephrol 13: 1463–1470, 2018PubMed10.2215/CJN.00380118)| false
BradyC, ChemalyER, LohrJW, ParkerMD: Veverimer: An advance in base therapy for metabolic acidosis. Ann Transl Med 8: 1331, 2020PubMed10.21037/atm-20-2827)| false
BushinskyDA, HostetterT, KlaernerG, StasivY, LockeyC, McNultyS, et al.: Randomized, controlled trial of TRC101 to increase serum bicarbonate in patients with CKD. Clin J Am Soc Nephrol13: 26–35, 2018PubMed
WessonDE, MathurV, TangriN, StasivY, ParsellD, LiE, et al.: Long-term safety and efficacy of veverimer in patients with metabolic acidosis in chronic kidney disease: A multicentre, randomised, blinded, placebo-controlled, 40-week extension. Lancet394: 396–406, 2019PubMed
RitterA, MohebbiN: Causes and consequences of metabolic acidosis in patients after kidney transplantation. Kidney Blood Press Res45: 792–801, 2020PubMed
RitterA, MohebbiN: Causes and consequences of metabolic acidosis in patients after kidney transplantation. Kidney Blood Press Res 45: 792–801, 2020PubMed10.1159/000510158)| false
GojowyD, SkibaK, BartmanskaM, KolonkoA, WiecekA, AdamczakM: Is metabolic acidosis a novel risk factor for a long-term graft survival in patients after kidney transplantation?Kidney Blood Press Res45: 702–712, 2020PubMed
GojowyD, SkibaK, BartmanskaM, KolonkoA, WiecekA, AdamczakM: Is metabolic acidosis a novel risk factor for a long-term graft survival in patients after kidney transplantation?Kidney Blood Press Res 45: 702–712, 2020PubMed10.1159/000508476)| false
DjamaliA, SinghT, MelamedML, SteinJH, AzizF, ParajuliS, et al.: Metabolic acidosis 1 year following kidney transplantation and subsequent cardiovascular events and mortality: An observational cohort study. Am J Kidney Dis73: 476–485, 2019PubMed
CervantesCE, MenezS, Monroy TrujilloJM, HanounehM: Clinical approach to a patient with an acid-base disturbance. Am J Kidney Dis 77: A9–A11, 2021PubMed10.1053/j.ajkd.2020.06.022)| false
BernsJS, KasbekarN: Highly active antiretroviral therapy and the kidney: An update on antiretroviral medications for nephrologists. Clin J Am Soc Nephrol1: 117–129, 2006PubMed
BernsJS, KasbekarN: Highly active antiretroviral therapy and the kidney: An update on antiretroviral medications for nephrologists. Clin J Am Soc Nephrol 1: 117–129, 2006PubMed10.2215/CJN.00370705)| false
Zand IraniA, AlmuwaisA, GibbonsH: Acquired pyroglutamic acidosis due to long-term dicloxacillin and paracetamol use. BMJ Case Rep13: e233306, 2020PubMed
JuurlinkDN, GosselinS, KielsteinJT, GhannoumM, LavergneV, NolinTD, et al.; EXTRIP Workgroup: Extracorporeal treatment for salicylate poisoning: Systematic review and recommendations from the EXTRIP Workgroup. Ann Emerg Med66: 165–181, 2015PubMed
JuurlinkDN, GosselinS, KielsteinJT, GhannoumM, LavergneV, NolinTD, ; EXTRIP Workgroup: Extracorporeal treatment for salicylate poisoning: Systematic review and recommendations from the EXTRIP Workgroup. Ann Emerg Med 66: 165–181, 2015PubMed10.1016/j.annemergmed.2015.03.031)| false
